9 results about "Gene engineering" patented technology

The present invention provides a cell suitable for gene engineering, cell engineering and cellular medicine, and a method for producing the same. The present invention provides a technique for removing repetitive sequences present in a specific gene region in two or more alleles, thereby facilitating gene targeting or sequencing in the region.

This invention discloses a PhlD gene based on translation rate optimization and its applications, belonging to the fields of genetic engineering and protein engineering. Without altering the amino acid sequence of the PhlD protein, this invention optimizes the translation rate of the original PhlD sequence through synonymous codon substitution, enabling rapid translation within the coding domains. Translation deceleration sites are introduced into the contiguous regions of the coding sequence domains, matching the ribosomal translation rate with the protein co-translational folding process, significantly improving the soluble expression level of the PhlD protein. The PhlD gene with optimized translation rate results in a 5.5-fold increase in the soluble expression level of the encoded PhlD protein compared to the original sequence. Engineered bacteria containing this optimized gene show a 4-fold increase in the yield of phloroglucinol during fermentation compared to the control. This provides a core gene resource for the efficient soluble expression of the PhlD protein and the industrial production of phloroglucinol.

The application discloses a preparation method and application of cell membrane-derived nanovesicles with specific targeting tumor and metastasis inhibition. The CD82 overexpression lung epithelial cell HBE cell strain is constructed through gene engineering, cell membranes are extracted in vitro, AS1411 aptamer is modified, and a chemotherapeutic drug, doxorubicin (DOX), is loaded to prepare an engineered nanovesicle drug delivery system. The engineered nanovesicle drug delivery system prepared by the application is proved to have multiple effects such as targeting triple-negative breast cancer, inhibiting metastasis and inducing triple-negative breast cancer cell apoptosis through in-vitro and in-vivo experiments. The application fills the gap of the extracellular vesicles as a drug carrier, and provides a new thought and scientific basis for the clinical treatment of triple-negative breast cancer.

The application discloses a construction method of Escherichia coli for producing NMN and application thereof, and belongs to the technical field of metabolic engineering. The method is characterized by taking Escherichia coli BL21 (DE3) as an original strain, introducing genes nampt, prs, Bcniap and zwf, knocking out related genes purR, ushA, pncC and pncA having degradation functions on PRPP, NMN and NAM and genes edd and eda related to an ED pathway, and constructing a gene engineering bacterium SZ-T08. The Escherichia coli disclosed by the application can make the yield of NMN reach 20.6 g / L, greatly reduce the production cost of NMN, and be more suitable for industrial application.

The application discloses a kind of human-computer collaborative intelligent ecosystem and method based on culture gene engineering.The system is driven by "meaning-use intention" dual-core architecture, establishes global language, knowledge, software positioning system, realizes the accuracy and traceability of intelligent behavior.The system can automatically identify and record the language points, knowledge points and algorithm innovation in the process of collaborative innovation, and realize real-time right protection and incentive through the contribution point mechanism.The application expands the specific application scenarios such as knowledge experience venue, intelligent resident vehicle and double-character chessboard, solves the technical problems such as semantic ambiguity of existing AI system, untraceable innovation and difficulty in interest allocation, and provides a complete solution for productivity, production relations and intellectual property protection in the new era of human-computer interaction.

The present application belongs to the technical field of metabolic engineering, and particularly relates to a recombinant microorganism for high-yield L-tryptophan, a construction method and application thereof. The present application constructs a recombinant Klebsiella oxytoca for high-yield L-tryptophan through gene engineering technology by screening knocked-out or added genes. The recombinant Klebsiella oxytoca of the present application can be used for high-efficiency production of L-tryptophan under fermentation conditions with glucose as a substrate, and the yield reaches 60 g / L, and the yield is 0.23 g / g. The present application provides a method for high-efficiency production of L-tryptophan by redirecting 2,3-butanediol synthesis metabolic flux through pyruvate to L-tryptophan synthesis, which has important economic benefits, good prospects, simple production process, low cost and high yield.

This invention discloses a bioactive molecule and its application in repairing aging lead-acid batteries, relating to the field of genetic engineering application technology. The molecule includes: a bioactive molecule DL1, whose amino acid sequence is shown in SEQ ID NO.2; a recombinant vector including the DL1 gene; a host cell including the recombinant vector; and an engineered bacterium BL21(DE3) / pET32a-DL1 constructed using genetic engineering methods. This strain can express DL1 protein intracellularly under the induction of an inducer. After purification, the DL1 protein can adsorb onto the positive and negative electrode surfaces of a lead-acid battery, altering its size by interacting with PbSO4, refining large PbSO4 particles, and increasing battery capacity, thereby achieving the purpose of repairing aging lead-acid batteries.

The application provides a method for regulating the pluripotency state of human embryonic stem cells and / or activating 8-cell-like cells NELFA The application belongs to the technical field of genetic engineering and provides a method for regulating the pluripotency state of human embryonic stem cells and / or activating 8-cell-like cells NELFA The application provides a method for regulating the pluripotency state of human embryonic stem cells. NELFA The application successfully discloses and verifies the role of the key positive regulator in driving the conversion of human embryonic stem cells into early embryonic stage cells, and provides a new technical means for efficiently obtaining primitive stem cells and 8-cell embryo-like cells, and then obtaining seed cells with expanded pluripotency.